58 related articles for article (PubMed ID: 31860321)
21. Biomimetically constructing a hypoxia-activated programmable phototheranostics at the molecular level.
Zhang H; Wu JH; Xue HZ; Zhang R; Yang ZS; Gao S; Zhang JL
Chem Sci; 2022 Aug; 13(31):8979-8988. PubMed ID: 36091208
[TBL] [Abstract][Full Text] [Related]
22. Polymer-Modified Liposomes for Drug Delivery: From Fundamentals to Applications.
Cao Y; Dong X; Chen X
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456613
[TBL] [Abstract][Full Text] [Related]
23. Delivery technologies for in utero gene therapy.
Palanki R; Peranteau WH; Mitchell MJ
Adv Drug Deliv Rev; 2021 Feb; 169():51-62. PubMed ID: 33181188
[TBL] [Abstract][Full Text] [Related]
24. Effects of Uncleavable and Cleavable PEG-Lipids with Different Molecular Weights on Accelerated Blood Clearance of PEGylated Emulsions in Beagle Dogs.
Jiao J; Luo X; Wang C; Jiao X; Liu M; Liu X; Wei L; Deng Y; Song Y
AAPS PharmSciTech; 2020 Mar; 21(3):106. PubMed ID: 32185548
[TBL] [Abstract][Full Text] [Related]
25. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes.
Xu H; Wang KQ; Deng YH; Chen DW
Biomaterials; 2010 Jun; 31(17):4757-63. PubMed ID: 20303164
[TBL] [Abstract][Full Text] [Related]
26. The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats.
Jiao J; Jiao X; Wang C; Wei L; Wang G; Deng Y; Song Y
AAPS PharmSciTech; 2020 Nov; 21(8):300. PubMed ID: 33140142
[TBL] [Abstract][Full Text] [Related]
27. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions.
Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X
Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215
[TBL] [Abstract][Full Text] [Related]
28. PEGylated nanoemulsions containing 1,2-distearoyl-sn-glycero-3-phosphoglycerol induced weakened accelerated blood clearance phenomenon.
Li Z; Gao X; Yan X; Deng Y; Ma H
Drug Deliv Transl Res; 2022 Oct; 12(10):2569-2579. PubMed ID: 35094294
[TBL] [Abstract][Full Text] [Related]
29. Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights.
Liu M; Chu Y; Liu H; Su Y; Zhang Q; Jiao J; Liu M; Ding J; Liu M; Hu Y; Dai Y; Zhang R; Liu X; Deng Y; Song Y
Mol Pharm; 2020 Apr; 17(4):1059-1070. PubMed ID: 31860321
[TBL] [Abstract][Full Text] [Related]
30. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
31. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
32. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
[TBL] [Abstract][Full Text] [Related]
33. [Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers].
Koide H; Asai T; Hatanaka K; Shimizu K; Yokoyama M; Ishida T; Kiwada H; Oku N
Yakugaku Zasshi; 2009 Dec; 129(12):1445-51. PubMed ID: 19952519
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
